Pharmacokinetics & Half-Life Engine
Multi-Compound Peptide Serum Plotter
Simulate blood serum concentration curves, peak-to-trough ratios, and steady-state accumulation across custom peptide stacks.
Simulation Horizon:
Simulated Serum Concentration Curve ($C_t$)
Tirzepatide (2.5mg / q7d)BPC-157 (250mcg / q1d)
Active Protocol Stack (2 Compounds)
#1Tirzepatide($t_1/2$: 120h)
mg
hours
Dual GIP/GLP-1 receptor agonist with a 5-day elimination half-life. Steady state achieved in ~22-25 days.
#2BPC-157($t_1/2$: 4h)
mcg
hours
Pentadecapeptide with rapid metabolic clearance (~4h half-life), typically studied with daily or BID dosing.
Steady-State Metrics
Tirzepatide
Peak Concentration ($C_max$):3.48
Trough Concentration ($C_min$):1.61
Peak-to-Trough Ratio:2.15x
Time to 95% Steady State:~22.5 days
Total Injections in Cycle:8 doses
BPC-157
Peak Concentration ($C_max$):98.31
Trough Concentration ($C_min$):4.34
Peak-to-Trough Ratio:22.63x
Time to 95% Steady State:~0.8 days
Total Injections in Cycle:56 doses
Pharmacokinetic Principles:
Steady state is reached at approximately 4.5 to 5 elimination half-lives. Splitting doses (e.g. twice-weekly instead of weekly) reduces the peak-to-trough fluctuation ratio, minimizing adverse side effect spikes and preventing sub-therapeutic troughs.Need to reconstitute these compounds into precise syringe units?
Use our Reconstitution Calculator with multi-peptide blend stack modes and automated BAC water volume optimization.